An Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan and Are Judged by the Investigator to Benefit From Continued QTI571 Treatment
Phase of Trial: Phase III
Latest Information Update: 19 Jun 2019
Price : $35 *
At a glance
- Drugs Imatinib (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 29 May 2017 Status changed from active, no longer recruiting to completed.
- 21 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 10 Feb 2014 Status changed from not yet recruiting to recruiting according to ClinicalTrials.gov record.